Enlarge / An electron micrograph of the respiratory syncytial virus (RSV). Getty | BSIP
The Food and Drug Administration issued the world’s first approval of a vaccine against respiratory syncytial virus (RSV), an achievement that researchers have worked toward for decades after a catastrophic clinical trial in the 1960s.
The vaccine, called Arexvy from pharmaceutical giant GSK, is approved for adults aged 60 and over. The Centers for Disease Control and Prevention will need to recommend the vaccine before it will be available for use. The agency’s advisory committee for immunizations is next scheduled to meet June 21 to 22
→ Continue reading at Ars Technica